Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan

Fig. 2

A PFS in patients with EGFR-mutant NSCLC treated with first-line, further-line, or no anti-angiogenesis agents. B OS in patients with EGFR-mutant NSCLC treated with first-line, further-line, or no anti-angiogenesis agents. EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer; OS, overall survival; PFS, progression-free survival

Back to article page